Cat. No. Name Size Price Add Cart
KI1124TG1013485 mg$176
TG10134810 mg$272
TG10134825 mg$592
TG10134850 mg$912

Chemical Characteristic

Product NameTG101348
SynonymsSAR302503
CAS No.936091-26-8
Molecular Weight 524.68
FormulaC27H36N6O3S
Chemical NameN-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
Smilesc1(cc(ccc1)Nc1nc(ncc1C)Nc1ccc(cc1)OCCN1CCCC1)S(=O)(=O)NC(C)(C)C
Chemical Structure

Biological activities

TG101348 is a selective small-molecule inhibitor of JAK2. The IC50 of TG101348 is 3 nM against JAK2. TG101348 also inhibits JAK2V617F with an IC50 of 3 nM. In contrast, TG101348 prevents Flt3 and Ret with IC50 of 15 and 48 nM, respectively. TG101348 has an IC50∼300-fold higher for the closely related JAK3. TG101348 is a less potent inhibitor of the JAK1 and TYK2 family members. TG101348 inhibits proliferation of both of a human erythroblast leukemia (HEL) cell line that harbors the JAK2V617F mutation and a murine pro-B cell line expressing human JAK2V617F (Ba/F3 JAK2V617F) The IC50 of TG101348 is 300 nM for either line.[1] TG10134 inhibits the growth of KITD816V-dependent mast cell leukemia cells by blocking JAK-STAT signaling.[2] TG101348 is well tolerated and produces significant reduction in disease burden of myelofibrosis.[3] TG101348 prevents the cytokine-independent growth of human erythroleukemia and Ba/F3-JAK2V617F cells with IC50 of 0.3 and 0.58 µM, respectively. TG101348 inhibits Ba/F3-MPLW515L cells with an IC50 of 0.62 µM. TG101348 significantly decreases the size of erythroid colonies (erythroid burst-forming unit) obtained from PV progenitor cells.[4]

References

[1] Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008, (4): 11-20.
[2] Lasho T, et al. Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia. 2010, 24(7): 1378-1380.
[3] Pardanani A, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011, 29(7): 789-796.
[4] Lasho TL, et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia. 2008, 22(9): 1790-1792.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.